Browse the evidence

Endogenous GLP-1 is primarily secreted by intestinal L-cells in response to nutrient contact, not by pancreatic alpha-cells.

Your body naturally produces GLP-1 from your intestines when you eat. This hormone helps regulate blood sugar and appetite. Dietary fiber and nutrients stimulate this natural release.

Native GLP-1 has a very short half-life (1-2 minutes) due to rapid degradation by the enzyme DPP-4, necessitating biochemically modified agonists for clinical use.

Your body breaks down natural GLP-1 very quickly. Medications like Ozempic or Wegovy are chemically modified to resist this breakdown, allowing them to work for days instead of minutes.

Daily supplementation with 2000 IU of vitamin D3 does not reduce the incidence of invasive cancer or major cardiovascular events in adults aged 50+ (men) and 55+ (women) compared to placebo.

Taking 2000 IU of vitamin D3 daily will not prevent cancer or heart attacks in generally healthy older adults, according to this major study. While vitamin D is essential for bone health, this specific dose does not offer the broad disease-prevention benefits often marketed. Focus on proven strategies for cancer and heart health prevention rather than relying on this supplement for those outcomes.

Vitamin D3 supplementation (2000 IU/day) does not reduce all-cause mortality in adults aged 50+ (men) and 55+ (women).

Taking 2000 IU of vitamin D3 daily will not help you live longer, based on this study. While it may support bone health, it does not appear to extend lifespan in older adults who are generally healthy.

Cellular senescence is a principle causative factor in organismal aging and facilitates aging-associated diseases.

This mechanism explains why aging tissues accumulate damage. Interventions targeting senescent cells (senolytics) are being researched to mitigate age-related diseases, though specific protocols are not detailed in this text.

Senescent cells secrete pro-inflammatory factors (SASP) that drive further senescence in neighboring cells and impair immune function, creating a self-perpetuating cycle of tissue damage.

The accumulation of senescent cells contributes to tissue aging. While senolytics (drugs that clear senescent cells) are in development, current practical steps involve supporting the body's natural clearance mechanisms through healthy lifestyle habits that reduce cellular stress.

Activation of the NLRP3 inflammasome in macrophages leads to the secretion of IL-1β and IL-18, which impair insulin signaling and contribute to beta-cell apoptosis in Type 2 Diabetes.

Chronic inflammation in fat tissue activates specific immune pathways (NLRP3 inflammasome) that release harmful cytokines (IL-1β). These cytokines damage insulin signaling and beta-cells. Addressing inflammation may help protect these cells.

Supplementation with 1 g/day of marine n-3 fatty acids (containing 840 mg EPA/DHA) does not reduce the incidence of major cardiovascular events or invasive cancer in a general population at usual risk.

Taking 1 gram of fish oil daily (providing 840mg EPA/DHA) does not significantly lower your risk of heart attacks, strokes, or cancer if you are otherwise at average risk. Focus on proven lifestyle factors instead.

Albumin binding via fatty acid derivatization extends the half-life of GLP-1 analogs, enabling once-daily (liraglutide) or once-weekly (semaglutide) dosing.

The drugs are designed to bind to albumin in the blood, which keeps them in the body longer. This allows for less frequent dosing (daily or weekly) compared to the natural hormone, which breaks down quickly.

Gut microbiota transplantation from high-cholesterol diet-fed mice to germ-free mice is sufficient to induce hepatic lipid accumulation, inflammation, and cell proliferation, demonstrating a causal role for microbiota in NAFLD-HCC.

Your gut bacteria are not just passengers; they can drive liver disease. If your diet has altered your gut bacteria to favor harmful types, those bacteria can directly cause liver inflammation and fat accumulation, even if you change your diet later.

Type 2 diabetes risk in Europeans is predominantly driven by common genetic variants of modest effect size, with no novel low-frequency variants of moderate-to-strong effect detected despite extensive sample sizes.

This research indicates that for most people of European ancestry, Type 2 Diabetes risk is largely determined by common genetic factors with small individual effects, rather than rare, high-impact mutations. This means lifestyle interventions remain critical because they address the environmental and physiological pathways (insulin secretion, action) that these genes influence, even if the genetic risk itself cannot be changed.

Without immediate and effective intervention, the global prevalence of adult overweight and obesity will continue to increase, reaching 3.80 billion adults by 2050.

The current trajectory of global obesity is unsustainable and will affect over half the adult population by 2050. Individuals and policymakers must move beyond simple awareness and implement aggressive, targeted interventions tailored to local contexts to prevent this crisis.

There is no clinical evidence from Randomized Controlled Trials (RCTs) for the gastrointestinal health effects of kombucha, miso, kimchi, or tempeh in humans.

Be cautious with claims about kombucha, kimchi, miso, and tempeh curing gut diseases. While they are healthy foods with interesting properties, there are no human clinical trials proving they treat gastrointestinal disorders. Enjoy them as part of a balanced diet, but don't rely on them as medicine yet.

Vitamin D3 supplementation at 4000 IU/day does not significantly reduce the risk of developing type 2 diabetes in adults at high risk who are not selected for vitamin D insufficiency.

If you are at high risk for type 2 diabetes, taking 4000 IU of Vitamin D3 daily will not significantly lower your risk of developing the disease unless you are severely deficient. Focus on proven lifestyle changes like weight management and physical activity instead of relying on this supplement for prevention.

Autoimmune thyroid disease (AITD) is significantly more prevalent in patients with Type 1 Diabetes (T1D) than in the general population, sharing common genetic susceptibility factors.

If you have Type 1 Diabetes, you are at a much higher risk for autoimmune thyroid disease (17-30% prevalence). Regular screening for thyroid function (TSH) and antibodies (TPO) is recommended, even if you feel healthy, to prevent complications and ensure optimal diabetes management.

Accelerated brain aging, specifically measured by a cognition-optimized plasma proteomic model (CognitionBrain), predicts Alzheimer's disease progression and cognitive decline independently of and as strongly as the current best blood biomarker, pTau-181.

For those concerned about Alzheimer's, this research suggests that a new blood test measuring brain-specific aging (CognitionBrain) is just as powerful as the current gold standard (pTau-181) and provides additional, independent information. Using both together offers the best prediction of cognitive decline. This highlights the importance of early, multi-faceted biomarker screening for those with family history or risk factors, rather than relying on a single test.

Hepatic insulin resistance, characterized by failure to suppress hepatic glucose production (gluconeogenesis and glycogenolysis), is a major feature of type 2 diabetes pathophysiology.

Managing fasting blood glucose often requires addressing hepatic glucose output, which can be influenced by weight loss and specific medications that target liver insulin sensitivity.

Using recovery biomarkers (such as doubly labeled water and urinary nitrogen) is the most effective method to validate self-reported dietary intake and quantify measurement error.

For accurate dietary assessment in research, use recovery biomarkers like doubly labeled water or urinary nitrogen to validate self-reported data.

Levothyroxine therapy does not improve thyroid-related symptoms or quality of life in older adults (≥65 years) with subclinical hypothyroidism.

If you are over 65 and have subclinical hypothyroidism (high TSH but normal T4), taking levothyroxine is unlikely to make you feel less tired or improve your quality of life. While the medication will lower your TSH levels, it does not appear to provide clinical benefits for symptoms in this age group.

Moderate to high intensity aerobic and strength exercise training does not slow cognitive impairment in people with mild to moderate dementia and may potentially worsen it, despite improving physical fitness.

For caregivers of individuals with mild to moderate dementia, prescribing moderate to high intensity aerobic and strength exercise is unlikely to slow cognitive decline and may slightly accelerate it on standard tests, though the clinical relevance is uncertain. However, this regimen significantly improves physical fitness (e.g., walking distance). Therefore, exercise should be prescribed primarily for physical health and functional independence, not for cognitive preservation, with careful monitoring for adverse events.

PPARgamma mutations (loss-of-function) cause familial partial lipodystrophy type 3 (FPLD3), characterized by lack of subcutaneous fat in extremities and metabolic complications like type 2 diabetes.

Fat distribution is partly genetic. If you have a rare condition like FPLD3, your fat distribution and metabolic risks are driven by specific genetic mutations.

GLP-2 (specifically the analogue teduglutide) promotes intestinal mucosal growth and nutrient absorption, making it an effective treatment for short bowel syndrome (SBS).

For patients with short bowel syndrome who rely on intravenous nutrition, teduglutide (a GLP-2 analogue) is an approved daily injection that helps the intestine grow and absorb more nutrients. This can reduce the need for intravenous feeding. It is specifically designed to resist breakdown in the body, making it effective for chronic use.

A metabolic biomarker score derived from 14 circulating metabolites (including lipids, amino acids, and inflammatory markers) provides significantly better prediction of 5- and 10-year all-cause mortality than conventional clinical risk factors across all adult ages.

Standard blood tests (cholesterol, blood pressure) are not enough to accurately predict your risk of dying in the next 5-10 years, especially as you age. A specialized metabolic blood test (NMR metabolomics) that looks at 14 specific markers (lipids, amino acids, inflammation) provides a much more accurate risk score. This tool is currently best used by clinicians to make high-stakes decisions, such as determining if an elderly patient is too frail for surgery, rather than for self-management.

Positive airway pressure (PAP) therapy, including CPAP and ASV, does not reduce the risk of major adverse cardiovascular events (ACS, stroke, vascular death) or all-cause mortality in adults with sleep apnea compared to no treatment or sham.

If you have sleep apnea, use PAP to improve your sleep quality and daytime alertness, as it does provide symptomatic relief. However, do not rely on PAP alone to protect your heart or prevent death. You must still follow standard cardiovascular prevention guidelines, such as managing blood pressure, cholesterol, and using antiplatelet therapy if indicated.